NCT01388491 - A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women | Biotech Hunter

Enrollment

293

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

HemostasisOral Contraceptive

Interventions

DRUG

desogestrel/ethinyl estradiol and ethinyl estradiol

DRUG

desogestrel/ethinyl estradiol

Trial Locations (27)

22159

Teva Investigational Site 32062, Hamburg

22359

Teva Investigational Site 32063, Hamburg

25123

Teva Investigational Site 30014, Brescia

27002

Teva Investigational Site 31012, Lugo

27100

Teva Investigational Site 30010, Pavia

28001

Teva Investigational Site 31010, Madrid

28009

Teva Investigational Site 31011, Madrid

34466

Teva Investigational Site 80015, Haifa

39112

Teva Investigational Site 32061, Magdeburg

45127

Teva Investigational Site 32064, Essen

53100

Teva Investigational Site 30016, Siena

53425

Teva Investigational Site 80013, Giv‘atayim

56126

Teva Investigational Site 30007, Pisa

60311

Teva Investigational Site 32065, Frankfurt

60439

Teva Investigational Site 32066, Frankfurt am Main

62304

Teva Investigational Site 80018, Tel Aviv

69379

Teva Investigational Site 80016, Tel Aviv

71705

Teva Investigational Site 80017, Modiin

80131

Teva Investigational Site 30013, Napoli

95123

Teva Investigational Site 30012, Catania

Unknown

Teva Investigational Site 80014, RishonLe'zio

09124

Teva Investigational Site 30009, Cagliari

08025

Teva Investigational Site 31017, Barcelona

08028

Teva Investigational Site 31015, Barcelona

08035

Teva Investigational Site 31014, Barcelona

08850

Teva Investigational Site 31016, Gava, Barcelona

01004

Teva Investigational Site 31009, Vitoria-Gasteiz

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY